|
|
|
|
|
|
|
The Rare Disease Patients Experience
|
|
When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
MedPharm Expands Relationship With Novan On Formulation Science
MedPharm Ltd, a leader in topical and transdermal drug delivery, has
expanded its relationship with the NASDAQ listed biopharmaceutical
company Novan Inc.
MedPharm has previously supported Novan by testing the company’s unique
formulations using its proprietary in vitro models to optimise Novan’s
formulations and de-risk product development.
More info >> |
|
 |
White Papers |
 |
|
Biosimilars In Emerging Markets: Is It A Level Playing Field?
PRA Health Sciences (PRA)
Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >> |
|
 |
Industry Events |
 |
Pharmapack Europe 2020
5-6 February 2020, Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France
More info >> |
|
|
|
